Skip to main content Help with accessibility Skip to main navigation

December 2021 updates to the website

The website has now been updated following November's LSCMMG

The following guidelines have been added/updated:

Overactive bladder guidance - New (Agreed, However awaiting further information prior to publishing) 

Dapagliflozin for T1 DM – TA 597 - Withdrawn and removed from the website

The following Items will be updated and added to the website following the next Strategic Commissioning Committee (SCC) Meeting:

Glycopyrronium - Hypersalivation in patients with Non - Parkinson's Disease

Upadacitinib - Upadacitinib for treating moderate rheumatoid arthritis (NICE TA744)